Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: A phase 3, multicentre, open-label, randomised trial

The Lancet Oncology

Volumn 13, Issue 7, 2012, Pages 696-706

  Pettengell, Ruth ^a   Coiffier, Bertrand ^b,c   Narayanan, Geetha ^d   de Mendoza, Fernando Hurtado ^e   Digumarti, Raghunadharao ^f   Gomez, Henry ^e   Zinzani, Pier Luigi ^g   Schiller, Gary ^h   Rizzieri, David ⁱ   Boland, Giles ^j,k   Cernohous, Paul ^l   Wang, Lixia ^l   Kuepfer, Christine ^l   Gorbatchevsky, Igor ^l   Singer, Jack W ^l,m  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b CENTRE HOSPITALIER LYON SUD   (France)

^c UNIVERSITÉ LYON 1   (France)

^d REGIONAL CANCER CENTRE   (India)

^e National Cancer Institute INEN and Oncosalud   (Peru)

^f NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ DUKE UNIVERSITY   (United States)

^j MASSACHUSETTS GENERAL HOSPITAL   (United States)

^k HARVARD MEDICAL SCHOOL   (United States)

^l Cell Therapeutics Inc   (United States)

^m UNIVERSITY OF WASHINGTON   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PIXANTRONE; RITUXIMAB;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BODY WEIGHT; CANCER PATIENT; CANCER RELAPSE; CARDIOTOXICITY; CELLULITIS; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; CONTROLLED STUDY; COUGHING; DEHYDRATION; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; DYSPNEA; EUROPE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HEART EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HISTOPATHOLOGY; HUMAN; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; INDIA; INFECTION; INJECTION SITE PAIN; INTENTION TO TREAT ANALYSIS; INTERACTIVE VOICE RESPONSE SYSTEM; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KIDNEY FAILURE; LEUKOPENIA; LUNG TOXICITY; LYMPHATIC SYSTEM DISEASE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC ACIDOSIS; METABOLIC DISORDER; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEOPLASM; NEPHROTOXICITY; NEUTROPENIA; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; NUTRITIONAL DISORDER; OPEN STUDY; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RUSSIAN FEDERATION; SALVAGE THERAPY; SIDE EFFECT; SKIN DISCOLORATION; SKIN TOXICITY; SOUTH AMERICA; STEM CELL TRANSPLANTATION; THORAX DISEASE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; UNITED KINGDOM; UNITED STATES; URINARY TRACT DISEASE; VASCULAR DISEASE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; ISOQUINOLINES; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; SALVAGE THERAPY; VENTRICULAR FUNCTION, LEFT;

EID: 84863113681     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70212-7     Document Type: Article

References (21)

1. National Comprehensive Cancer Network guidelines, version 2.2011. Diffuse large B-cell lymphoma (accessed March 23, 2011). http://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf.
2. Swain S, Whaley FS, Ewer MS Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003, 97:2869-2879.
3. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010, 28:4184-4190.
4. Hagemeister FB Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Cancer Chemother Pharmacol 2002, 49(suppl 1):S13-S20.
5. Krapcho AP, Maresch MJ, Hacker MP, et al. Anthracene-9, 10-diones and aza bioisosteres as antitumor agents. Curr Med Chem 1995, 2:803-824.
6. Singal KS, Iliskovic N Doxorubicin-induced cardiomyopathy. N Engl J Med 1998, 339:900-905.
7. Mordente A, Meucci E, Martorana G, Giardina B, Minotti G Human heart cytosolic reductases and anthracycline cardiotoxicity. IUBMB Life 2001, 52:83-88.
8. Mordente A, Meucci E, Silvestrini A, Martorana GE, Giardina B New developments in anthracycline-induced cardiotoxicity. Curr Med Chem 2009, 16:1656-1672.
9. Cavalletti E, Crippa L, Mainardi P, et al. Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone. Invest New Drugs 2007, 25:187-195.
10. Borchmann P, Morschhauser F, Parry A, et al. Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas. Haematologica 2003, 88:888-894.
11. Webb MS, Saltman DL, Connors JM, Goldie JH A literature review of single agent treatment of multiply relapsed aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2002, 43:975-982.
12. Tan BR, Bartlett NL Treatment advances in non-Hodgkin's lymphoma. Expert Opin Pharmacother 2000, 1:451-466.
13. Fossa A, Santoro A, Hiddemann W, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 1999, 17:3786-3792.
14. Coiffier B Immunochemotherapy: the new standard in aggressive non-Hodgkin's lymphoma in the elderly. Semin Oncol 2003, 30(1 suppl 2):21-27.
15. Cheson BD, Horning SJ, Coiffer B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999, 17:1244-1352.
16. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005, 23:667-675.
17. Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008, 26:1-6.
18. Rule S, Tighe M, Davies S, Johnson S Vinorelbine in the treatment of lymphoma. Hematol Oncol 1998, 16:101-105.
19. Germann N, Brienza S, Rotarski M, et al. Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients. Ann Oncol 1999, 10:351-354.
20. Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011, 22:1622-1627.
21. Mukherji D, Pettengell R Pixantrone for the treatment of aggressive non-Hodgkin lymphoma. Expert Opin Pharmacother 2010, 11:1915-1923.